Scientists at the University of Southern California found that inhaled cannabidiol (CBD) reduced key drivers of neuroinflammation in mice with Alzheimer’s disease [1].
This discovery is significant because calming the brain's immune response may protect neurons and mitigate the overall pathology of the disease [1, 3].
The researchers used a transgenic mouse model of Alzheimer's to test the effects of the compound [1, 2]. According to the study, the administration of inhaled CBD helped reverse brain damage and reduced the inflammatory markers that typically drive the progression of the condition [2, 3].
Neuroinflammation is a critical component of Alzheimer's disease. When the brain's immune system becomes overactive, it can cause further damage to healthy neurons. The USC team said that targeting this immune response could slow the decline of cognitive functions [1, 3].
By delivering the CBD via inhalation, the researchers were able to observe a reduction in the drivers of this inflammation [1]. This method of delivery suggests a potential pathway for future therapeutic interventions in humans, though the study remained focused on laboratory animals [1, 2].
The findings indicate that the compound works by calming the brain's immune response, which in turn may protect the brain from the cumulative damage associated with the disease [1, 3].
“Inhaled CBD reduced key drivers of neuroinflammation in a transgenic mouse model of Alzheimer’s disease.”
While these results are promising, they are limited to transgenic mouse models. The transition from animal success to human clinical efficacy is a high hurdle in Alzheimer's research. If these results translate to humans, inhaled CBD could offer a non-invasive method to manage neuroinflammation, potentially shifting treatment focus toward immune modulation alongside traditional amyloid-targeting therapies.
